Drug Trial Radar · NCT06341621
Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib
Last checked: Nov 20, 2026Latest source record: Apr 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,900
Planned (sponsor's estimate)
Start
Apr 2, 2024
Primary completion
Feb 25, 2027
Study completion Jan 1, 2029
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomized, open-label, multicenter phase III study to explore chemotherapy omission in ER+/HER2-endocrine-sensitive breast cancer with 1-3 positive lymph nodes receiving extended (3 year) adjuvant abemaciclib
Conditions
- Breast Cancer
Interventions
3-year abemaciclib without chemoDrug
aromatase inhibitors (± ovarian suppression) plus 3-year abemaciclib (100mg bid) without chemotherapy.
treatment of physician's choiceDrug
treatment of physician's choice including whether to receive chemotherapy, chemotherapy regimen and endocrine therapy regimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive disease free survivalTime frame: 5 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhimin Cancer Shao
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.